It has been implicated in enhancing HCC metastasis through the mediation of the p-ERK1/2/p-SMAD2/Snail pathway, and its inhibition has been shown to reverse drug resistance to regorafenib in HCC (Zhang et al., 2020). Here, SMAD2 is linked to hepatocellular carcinoma.